{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-000801","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.577909+00:00","generated_at":"2026-05-28T05:19:03.304324+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NRXP subsidiary HOPE signs $27M term sheet with Smith & Sauer; $25M preferred equity, $2M common","bullets":["Smith & Sauer to purchase $25M Series A Preferred in HOPE convertible into 1/3 of fully diluted equity, with 15% dividend.","$2M purchase of NRXP common at $2.75/share (above recent close); investor also buys 500K shares from existing holders at $2.75.","Warrants for 3M NRXP shares at $3.00/sh with 24-month term, plus royalties on product sales up to $250M cumulative return.","Smith & Sauer gets board seats at both HOPE and NRXP; funding to support clinic acquisitions and NRX-100/NRX-101 development.","Closing subject to definitive agreements and standard conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-000801","json":"https://secwatch.observer/filing/0001437749-25-000801.json","markdown":"https://secwatch.observer/filing/0001437749-25-000801.md","text":"https://secwatch.observer/filing/0001437749-25-000801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925000801/0001437749-25-000801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925000801/nrxp20250109_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:19:03.304324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}